8-K filed Sep 9, 2026 at 07:05 ET
Kura Oncology formed a wholly owned subsidiary, Caspian Therapeutics, to develop next-generation menin inhibitors for diabetes and cardiometabolic diseases. Caspian raised $50.0M in a Series A preferred stock private financing, with Kura investing $4.3M, leaving Kura with ~49.2% ownership. Kura contributed assets including KO-7246 and related IP to Caspian in exchange for Caspian common stock and a $1.5M reimbursement, and entered into an intercompany services agreement. This spin-out of a non-core pipeline asset into a separately capitalized entity is a positive catalyst, unlocking value from Kura's menin platform beyond oncology without diluting Kura shareholders.